TerrierBAmouraZRavaudP, et al.
Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum2010;
62: 2458–2466.
2.
Diaz-LagaresCCrocaSSangleS, et al.
Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev2012;
11: 357–364.
3.
ParodisIStockfeltMSjowalCB.Cell therapy in systemic lupus erythematosus: from rationale to clinical practice. Front Med (Lausenne)2020;
7: 316.
4.
ReddyVKleinCIsenbergDA, et al.
Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford)2017;
56: 1227–1237.
5.
FurieRArocaGAlvarezA, et al.
A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with mycophenolate mofetil in patients with active class III or IV lupus nephritis. Arthritis Rheumatol2019;
71: 0939.
6.
MyslerEFSpindlerAJGuzmanR, et al.
Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheumatol2013;
65: 2368–2379.
7.
MasoudSMcAdooSPBediRCairnsTDLightstoneL.Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology (Oxford)2018;
57: 1156–‐1161.
LeiLMuhammadSAl-ObaidiM, et al.
Successful use of ofatumumab in two cases of early-onset juvenile SLE with thrombocytopenia caused by a mutation in protein kinase C δ. Pediatr Rheumatol Online J2018;
16: 61.
